telehealth weight loss consultations tirzepatide injections obesity treatment is evolving rapidly, with newer medications now offering significant and sustained when combined with lifestyle modification., GLP-1 and dual GIP/GLP-1 therapies such as Tirzepatide Weight Loss Injections •

Introduction Alcohol use disorder (AUD) affects 29.5 million individuals greater than 12 years old and is one of the top causes of avoidable deaths, causing approximately 178,000 deaths annually ( The Alcohol Use Disorders Identification Test (AUDIT) is a screening tool developed by the World Health Organization (WHO) to help individuals recognize potential alcohol-related issues ( GLP-1 receptor agonists, developed initially as diabetes medications, have gained popularity due to their ability to suppress appetite and reduce the speed of gastric emptying, resulting in weight loss ( This case report serves to augment the existing body of evidence supporting the favorable impact of GLP-1 receptor agonists, not only on diabetes and weight management but also on AUD

Suitable candidates typically include adults with a Body Mass Index (BMI) of 30 kg/m or higher, indicating obesity, or those with a BMI of at least 27 kg/m and weight-related health conditions, such as elevated cholesterol levels, hypertension, or type 2 diabetes

Head-drop: a frequent feature in late onset myasthenia gravis

[DOI] [PubMed] [Google Scholar] 59.Thong HY, Chu CY, Chiu HC, others Methimazole-induced antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis and lupus-like syndrome with a cutaneous feature of vesiculo-bullous systemic lupus erythematosus